Clare L. Scott
Royal Women's Hospital(AU)The University of Melbourne(AU)Baylor College of Medicine(US)Walter and Eliza Hall Institute of Medical Research(AU)Peter MacCallum Cancer Centre(AU)Wellcome Sanger Institute(GB)Melbourne Health(AU)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, Ovarian cancer diagnosis and treatment, BRCA gene mutations in cancer, Cancer Genomics and Diagnostics, DNA Repair Mechanisms
Most-Cited Works
- → Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial(2010)2,279 cited
- → Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer(2012)1,873 cited
- → Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial(2017)1,842 cited
- → Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)1,678 cited
- → Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial(2014)1,433 cited